Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
about
Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsA tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blottingStatin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma.Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Targeting tumor cell metabolism with statins.Human T-lymphotropic virus proteins and post-translational modification pathwaysSimvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.
P2860
Q27027458-0275E58C-F921-4DFD-AE8A-D64CE2F40175Q33812895-43D72067-6CB7-440E-94AA-9575A6CCD24DQ35186039-45B19A99-6D9D-4D0D-B1C7-2352960A29FCQ36838089-A84DB309-ECCF-456D-99C5-6BD1FE592284Q37113976-B6C54811-D57C-4909-B7A4-9731A6C284EFQ37981833-1B23E6C1-B1A1-4C39-8711-4A74C0FBAAD3Q38156859-D06226AD-3CE3-4AAE-AC15-D3E1C379D891Q38952701-6320AA59-C7CC-4CE8-98BC-2ACBB11D2C46Q39818295-2EDB4635-C7FC-4EAB-BA18-6AE35B08AC75Q39998302-05D4E36D-CE5F-4572-AC31-B608A83C3B8DQ53297858-81885B28-9941-4F41-9972-EE6D48B1D903
P2860
Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Combining prenylation inhibito ...... ing in multiple myeloma cells.
@en
Combining prenylation inhibito ...... ing in multiple myeloma cells.
@nl
type
label
Combining prenylation inhibito ...... ing in multiple myeloma cells.
@en
Combining prenylation inhibito ...... ing in multiple myeloma cells.
@nl
prefLabel
Combining prenylation inhibito ...... ing in multiple myeloma cells.
@en
Combining prenylation inhibito ...... ing in multiple myeloma cells.
@nl
P2093
P2860
P1476
Combining prenylation inhibito ...... ing in multiple myeloma cells.
@en
P2093
Arnold Ganser
Christoph W M Reuter
Dietrich Peest
Erdem Aydilek
Michael A Morgan
Tarkan Sebil
P2860
P304
P356
10.1111/J.1365-2141.2005.05696.X
P407
P577
2005-09-01T00:00:00Z